Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + cyclophosphamide + dexamethasone
- Development stage
- Phase 4
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of thalidomide, cyclophosphamide, and dexamethasone used primarily for the treatment of multiple myeloma. This oral regimen has shown effectiveness in both newly diagnosed patients and those with relapsed/refractory disease. The combination works through multiple mechanisms including immunomodulatory effects, direct anti-tumor activity, and anti-inflammatory properties.
- Other names
- CTDThaCyDex
02
Targets
CRBN (Cereblon)DNAGR (Glucocorticoid receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on thalidomide + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + cyclophosphamide + dexamethasone.